HURA TuHURA Biosciences, Inc./NV
Pharmaceutical Preparations · Nasdaq · SEC CIK 1498382 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-2.2%
TTM EPS YoY-47.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-167.5%
ROA-96.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets47.7%
Debt / equity0.49x
Current ratio0.47x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-20.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $0 |
| R&D expense | $20.53M | $13.34M |
| SG&A expense | $7.58M | $3.87M |
| Interest expense | $625,283 | $4.14M |
| Pretax income | -$30.05M | -$21.68M |
| Income tax | $1,600 | $3,768 |
| Net income | -$30.05M | -$21.68M |
| EPS (basic) | -0.63 | -1.21 |
| EPS (diluted) | -0.63 | -1.21 |
| Weighted avg. shares (diluted) | 47.93M | 18.66M |
| Balance sheet | ||
| Cash & equivalents | $3.62M | $12.66M |
| Current assets | $4.62M | $19.61M |
| PP&E, net | $300,639 | $123,366 |
| Goodwill | $10.74M | — |
| Total assets | $27.35M | $19.97M |
| Current liabilities | $5.92M | $5.33M |
| Total liabilities | $6.42M | $5.37M |
| Shareholders' equity | $20.93M | $14.59M |
| Shares outstanding | 59.34M | 12.17M |
| Cash flow statement | ||
| Operating cash flow | -$27.63M | -$14.73M |
| Capital expenditure | $76,083 | $57,906 |
| Free cash flow | -$27.71M | -$14.79M |
| Investing cash flow | -$1.34M | -$6.05M |
| Financing cash flow | $19.93M | $29.77M |
| Depreciation & amortization | $71,265 | $116,710 |
| Stock-based compensation | $6.42M | $1.96M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.